View generic Fabhalta availability for more details. 200 mg Fabhalta oral capsule from $46,853.75 for 60 capsules · Important: When there is a range of pricing, consumers should normally expect to pay the lower price.

Adults with PNH who were prescribed ... cost people $0 per month§ · While the listed (or wholesale) FABHALTA price as of March 24, 2025, is $46,561.64 per 30-day fill, many people pay significantly less....

October 1, 2025 - The cost of Fabhalta can vary based on several factors, including your insurance coverage and the pharmacy you use. Coupons and drug savings programs can also lower the price you’ll pay for Fabhalta.

... Fabhalta Co-Pay Plus: Eligible commercially insured patients may pay $0 per prescription with a maximum savings of $20,000 and up to $1,000 for qualifying vaccination costs (excluding administrative fees) per calendar year.

*Co-Pay Plus: Limitations apply. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Patients with commercial insurance coverage for FABHALTA may receive up to $20,000 in annual co-pay benefits for the cost of FABHALTA and up to $1,000 for qualifying vaccination costs.

Fabhalta (iptacopan) is only available through a special Risk Evaluation and Mitigation Strategies (REMS) program since it raises the risk for serious infections. ... To find your copay price, choose your prescription and Medicare plan above. Every Medicare price in this table is for one 30 day fill of the medication.

previously treated and treatment-naive patients, is the only FDA-approved Factor B inhibitor of · the immune system's complement pathway, which drives complement-mediated hemolysis in · PNH. The price for FABHALTA reflects the benefits it may provide people living with PNH and · also considers the overall value FABHALTA may provide to the healthcare system compared to · currently available therapies. The branded therapies used for reference were Ultomiris and

March 13, 2026 - The discounted price is applied immediately at the point of dispensing. The card can be used repeatedly for all your prescriptions — it never expires. The Rx Advantage Card is available to anyone in the United States — insured, underinsured, or uninsured.

July 27, 2026 - Fabhalta is an oral medication filled at a pharmacy, so it falls under Part D — meaning the 2026 Part D out-of-pocket cap of $2,100 per year applies, and at this price you’ll reach it immediately and then owe nothing more for covered Part D drugs that year.

1 week ago - Fabhalta was approved to treat patients with paroxysmal nocturnal hemoglobinuria and will have a wholesale acquisition cost of $550,000 per year.

April 1, 2024 - Magnitude of the lifetime impact ... Value for Money · Iptacopan has been approved by the FDA (branded as Fabhalta®) and carries a list price of $550,377 per year....

Patients with commercial insurance coverage for FABHALTA may receive up to $20,000 in annual co-pay benefits for the cost of FABHALTA and up to $1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year.

For remaining patients, the out-of-pocket cost for the product varies and may be as high, as the total cost of the product. §Top 80% time to first fill. Enter your zip code or NPI number to see local FABHALTA coverage for your patients. Relevant medical records and clinical notes that support treatment · Appropriate clinical information from the Prescribing Information

The price is determined by the manufacturer. When a medicine is innovative and new, the price is usually high. Over time, the production levels may go up and the price may change, but most of our patients don't have the time to wait.

August 15, 2024 - Regarding pricing, Novartis has decided to maintain Fabatan's listing price at $550,000. Though this is higher than the wholesale cost of approximately $120,000 for Filspari, Novartis U.S. President Victor Burto emphasized that the pricing reflects ...

to $20,000 in annual co-pay benefits for the cost of FABHALTA and up to $1,000 for qualifying vaccination · costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar · year. Program not valid (i) under Medicare, Medicaid, TRICARE, VA, ...

August 8, 2024 - Novartis has kept Fabhalta’s list price unchanged at $550,000, which is much higher than the roughly $120,000 cost of Travere Therapeutics’ rival therapy Filspari. (Novartis) The first horse carrying Novartis’ immunoglobulin A nephropathy ...

Patients with commercial insurance coverage for FABHALTA may receive up to $20,000 in annual co-pay benefits for the cost of FABHALTA and up to $1,000 for qualifying vaccination costs (excluding administrative fees). Patient is responsible for any costs once limit is reached in a calendar year.